Stephen P Chelko1, Angeliki Asimaki2, Justin Lowenthal3, Carlos Bueno-Beti2, Djahida Bedja1, Arianna Scalco4, Nuria Amat-Alarcon1, Peter Andersen1, Daniel P Judge5, Leslie Tung3, Jeffrey E Saffitz6. 1. Departments of Medicine (S.P.C., D.B., N.A.-A., P.A.), Johns Hopkins School of Medicine, Baltimore, MD. 2. St. George's University of London, UK (A.A., C.B.-B.). 3. Biomedical Engineering (J.L., L.T.), Johns Hopkins School of Medicine, Baltimore, MD. 4. Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, Italy (A.S.). 5. Department of Medicine, Medical University of South Carolina, Charleston (D.P.J.). 6. Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA (J.E.S.).
Abstract
BACKGROUND: Inflammation is a prominent feature of arrhythmogenic cardiomyopathy (ACM), but whether it contributes to the disease phenotype is not known. METHODS: To define the role of inflammation in the pathogenesis of ACM, we characterized nuclear factor-κB signaling in ACM models in vitro and in vivo and in cardiac myocytes from patient induced pluripotent stem cells. RESULTS: Activation of nuclear factor-κB signaling, indicated by increased expression and nuclear accumulation of phospho-RelA/p65, occurred in both an in vitro model of ACM (expression of JUP2157del2 in neonatal rat ventricular myocytes) and a robust murine model of ACM (homozygous knock-in of mutant desmoglein-2 [Dsg2mut/mut]) that recapitulates the cardiac manifestations seen in patients with ACM. Bay 11-7082, a small-molecule inhibitor of nuclear factor-κB signaling, prevented the development of ACM disease features in vitro (abnormal redistribution of intercalated disk proteins, myocyte apoptosis, release of inflammatory cytokines) and in vivo (myocardial necrosis and fibrosis, left ventricular contractile dysfunction, electrocardiographic abnormalities). Hearts of Dsg2mut/mut mice expressed markedly increased levels of inflammatory cytokines and chemotactic molecules that were attenuated by Bay 11-7082. Salutary effects of Bay 11-7082 correlated with the extent to which production of selected cytokines had been blocked. Nuclear factor-κB signaling was also activated in cardiac myocytes derived from a patient with ACM. These cells produced and secreted abundant inflammatory cytokines under basal conditions, and this was also greatly reduced by Bay 11-7082. CONCLUSIONS: Inflammatory signaling is activated in ACM and drives key features of the disease. Targeting inflammatory pathways may be an effective new mechanism-based therapy for ACM.
BACKGROUND:Inflammation is a prominent feature of arrhythmogenic cardiomyopathy (ACM), but whether it contributes to the disease phenotype is not known. METHODS: To define the role of inflammation in the pathogenesis of ACM, we characterized nuclear factor-κB signaling in ACM models in vitro and in vivo and in cardiac myocytes from patient induced pluripotent stem cells. RESULTS: Activation of nuclear factor-κB signaling, indicated by increased expression and nuclear accumulation of phospho-RelA/p65, occurred in both an in vitro model of ACM (expression of JUP2157del2 in neonatal rat ventricular myocytes) and a robust murine model of ACM (homozygous knock-in of mutant desmoglein-2 [Dsg2mut/mut]) that recapitulates the cardiac manifestations seen in patients with ACM. Bay 11-7082, a small-molecule inhibitor of nuclear factor-κB signaling, prevented the development of ACM disease features in vitro (abnormal redistribution of intercalated disk proteins, myocyte apoptosis, release of inflammatory cytokines) and in vivo (myocardial necrosis and fibrosis, left ventricular contractile dysfunction, electrocardiographic abnormalities). Hearts of Dsg2mut/mutmice expressed markedly increased levels of inflammatory cytokines and chemotactic molecules that were attenuated by Bay 11-7082. Salutary effects of Bay 11-7082 correlated with the extent to which production of selected cytokines had been blocked. Nuclear factor-κB signaling was also activated in cardiac myocytes derived from a patient with ACM. These cells produced and secreted abundant inflammatory cytokines under basal conditions, and this was also greatly reduced by Bay 11-7082. CONCLUSIONS: Inflammatory signaling is activated in ACM and drives key features of the disease. Targeting inflammatory pathways may be an effective new mechanism-based therapy for ACM.
Authors: Stephen P Chelko; Angeliki Asimaki; Peter Andersen; Djahida Bedja; Nuria Amat-Alarcon; Deeptankar DeMazumder; Ravirasmi Jasti; Calum A MacRae; Remo Leber; Andre G Kleber; Jeffrey E Saffitz; Daniel P Judge Journal: JCI Insight Date: 2016-04-21
Authors: Raffaella Lombardi; Maria da Graca Cabreira-Hansen; Achim Bell; Richard R Fromm; James T Willerson; A J Marian Journal: Circ Res Date: 2011-10-20 Impact factor: 17.367
Authors: M P Coghlan; A A Culbert; D A Cross; S L Corcoran; J W Yates; N J Pearce; O L Rausch; G J Murphy; P S Carter; L Roxbee Cox; D Mills; M J Brown; D Haigh; R W Ward; D G Smith; K J Murray; A D Reith; J C Holder Journal: Chem Biol Date: 2000-10
Authors: Subarna Bhattacharya; Paul W Burridge; Erin M Kropp; Sandra L Chuppa; Wai-Meng Kwok; Joseph C Wu; Kenneth R Boheler; Rebekah L Gundry Journal: J Vis Exp Date: 2014-09-23 Impact factor: 1.355
Authors: Sam Strickson; David G Campbell; Christoph H Emmerich; Axel Knebel; Lorna Plater; Maria Stella Ritorto; Natalia Shpiro; Philip Cohen Journal: Biochem J Date: 2013-05-01 Impact factor: 3.857
Authors: Changsung Kim; Johnson Wong; Jianyan Wen; Shirong Wang; Cheng Wang; Sean Spiering; Natalia G Kan; Sonia Forcales; Pier Lorenzo Puri; Teresa C Leone; Joseph E Marine; Hugh Calkins; Daniel P Kelly; Daniel P Judge; Huei-Sheng Vincent Chen Journal: Nature Date: 2013-01-27 Impact factor: 49.962
Authors: Marta Pérez-Hernández; Chantal J M van Opbergen; Navratan Bagwan; Christoffer Rasmus Vissing; Henning Bundgaard; Mario Delmar; Alicia Lundby; Grecia M Marrón-Liñares; Mingliang Zhang; Estefania Torres Vega; Andrea Sorrentino; Lylia Drici; Karolina Sulek; Ruxu Zhai; Finn B Hansen; Alex H Christensen; Søren Boesgaard; Finn Gustafsson; Kasper Rossing; Eric M Small; Michael J Davies; Eli Rothenberg; Priscila Y Sato; Marina Cerrone; Thomas Hartvig Lindkær Jensen; Klaus Qvortrup Journal: Circulation Date: 2022-08-12 Impact factor: 39.918
Authors: J Lukas Laws; Megan C Lancaster; M Ben Shoemaker; William G Stevenson; Rebecca R Hung; Quinn Wells; D Marshall Brinkley; Sean Hughes; Katherine Anderson; Dan Roden; Lynne W Stevenson Journal: Circ Res Date: 2022-05-26 Impact factor: 23.213
Authors: Chantal J M van Opbergen; Navratan Bagwan; Alicia Lundby; Mario Delmar; Svetlana R Maurya; Joon-Chul Kim; Abigail N Smith; Daniel J Blackwell; Jeffrey N Johnston; Björn C Knollmann; Marina Cerrone Journal: Circulation Date: 2022-05-01 Impact factor: 39.918
Authors: Eric D Smith; Neal K Lakdawala; Nikolaos Papoutsidakis; Gregory Aubert; Andrea Mazzanti; Anthony C McCanta; Prachi P Agarwal; Patricia Arscott; Lisa M Dellefave-Castillo; Esther E Vorovich; Kavitha Nutakki; Lisa D Wilsbacher; Silvia G Priori; Daniel L Jacoby; Elizabeth M McNally; Adam S Helms Journal: Circulation Date: 2020-05-06 Impact factor: 29.690
Authors: Stephen P Chelko; Gizem Keceli; Andrea Carpi; Nunzianna Doti; Jacopo Agrimi; Angeliki Asimaki; Carlos Bueno Beti; Matthew Miyamoto; Nuria Amat-Codina; Djahida Bedja; An-Chi Wei; Brittney Murray; Crystal Tichnell; Chulan Kwon; Hugh Calkins; Cynthia A James; Brian O'Rourke; Marc K Halushka; Edon Melloni; Jeffrey E Saffitz; Daniel P Judge; Menotti Ruvo; Richard N Kitsis; Peter Andersen; Fabio Di Lisa; Nazareno Paolocci Journal: Sci Transl Med Date: 2021-02-17 Impact factor: 17.956
Authors: Arianna Scalco; Cristina Liboni; Roberta Angioni; Anna Di Bona; Mattia Albiero; Nicole Bertoldi; Gian Paolo Fadini; Gaetano Thiene; Stephen P Chelko; Cristina Basso; Antonella Viola; Marco Mongillo; Tania Zaglia Journal: J Clin Med Date: 2021-04-26 Impact factor: 4.241